Powered by

Novaliq GmbH Announces Licensing Agreement with AFT Pharmaceuticals for the Distribution of NovaTears®

Mar 20, 2017 - Business Wire

Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced a strategic licensing agreement with AFT Pharmaceuticals (AFT) for the commercialization of Novaliq's lead product NovaTears® in Australia and New Zealand.

NovaTears is Novaliq's first commercially available ophthalmic product for the treatment of evaporative dry eye diseases (DEDs). In Europe, NovaTears is...